CenoBiologics

Humabiologics, Inc is a regenerative medicine startup founded by scientists and tissue industry experts with scientific, quality, regulatory and technology transfer expertise to address the gap between the gift of donated human tissues and researchers. Humabiologics is dedicated to extending the gift of donation by developing and commercializing high quality, supply-stable and affordable human-derived biomaterials from tissue and organs for regenerative medicine therapies that complies with the FDA's 21 CFR 1271 regulation and the tissue industry quality system standards. Our products can be used alone or in conjunction with other biomaterials in various fields including tissue engineering, regenerative medicine, bio-printing, diagnostics & screening, pharmacology, cell culture, and many other life sciences applications. We are dedicated to bridging the gap between the gift of donated human tissues and researchers. We partner with academic and industry institutions to develop and provide affordable, supply-stable, and high quality human-derived biomaterials for researchers to innovate regenerative medicine therapies to address debilitating diseases and improve the quality of life for patients. We strive to provide a high quality and stable supply of human-derived biomaterials at an affordable price to help researchers innovate regenerative medicine therapies to Empower Tomorrow's Innovations. Our laboratory is able to help you define what you are working on and provide independent analysis you can use to verify your results. We have over 20 years combined experience in navigating complex regulatory submissions to help you get from idea to approved therapies using biomaterials and human collagen.

BioGenix grew out of the recognition that regenerative medicine presents hope to patients who suffer from diseases or injuries. BioGenix has a longstanding reputation for building and maintaining supportive relationships with clinicians. We are equally committed to providing high-quality allograft products to clinicians all over the world. BioGenix adheres to stringent guidelines per Current Good Manufacturing Practices (cGMP), Current Good Tissue Practice (cGTP), State Regulations, AATB guidelines, FDA requirements for Human Cells, and Cellular and Tissue-based Products (HCT/P). While the BioGenix products are produced in an FDA compliant laboratory, it has not been approved by the FDA for treatment effectiveness. BioGenix advances this mission with the world's most advanced umbilical cord allograft products. Realizing the intrinsic value of transparency, BioGenix is committed to consistently share cutting-edge studies about innovative therapies and life science principles that support the natural healing of the body. Our commitment to excellence serves as the foundation to our core operating ethos culminating in the best safety track record within the industry.

Our products aim to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. We provide high-throughput instruments for culturing, analyzing, optimization and handling biological cells. Founded in 2016, BICO (formerly CELLINK) is the world’s leading bioconvergence company, organized into three business areas: Biosciences, Bioautomation, and Bioprinting. Using a combination of robotics, artificial intelligence, advanced genomics, and 3D bioprinting, our innovative technologies enable researchers and practitioners in the life sciences to conduct cell line development, perform high-throughput drug screening and diagnostics, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. BICO is the future of life-saving treatments, as we enable our customers to improve people’s health and lives. CYTENA Bioprocess Solutions Co., Ltd (CBS) is founded in 2018 as a subsidiary of BICO (formerly CELLINK) , a world leading bioconvergence group. CYTENA Bioprocess Solutions focuses on offering bioprocess solutions for, but not limited to pharmaceuticals and top research institutes. We have established collaboration with leading academic institutes and industrial companies in researching, development, and application.

ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough proprietary technology platform for scalable, high-throughput tissue generation.Our team brings highly relevant experience from the biotech industry and expertise in cell biology, tissue culture automation, and translational research from top academic institutions across Europe and the US. ClexBio is a pre-clinical stage regenerative medicine company with a breakthrough proprietary technology platform for scalable, high-throughput tissue generation.

Our products are the first choice of orthopedists, trauma and spine surgeons, sports physicians, as well as dental implantologists, oral and maxillofacial surgeons and specialists in surgical dentistry. Our curasan team develops, manufactures and distributes biomaterials for bone and tissue regeneration. Under the CERASORB® umbrella brand, we have established an innovative product line for bone and tissue regeneration. The phase purity of the β-tricalcium phosphate we produce and use in CERASORB® is considered the reference standard* in the market worldwide. The expansive innovative products are certified by many international regulatory authorities and available in around 50 countries worldwide. An innovative product pipeline for bone and tissue regeneration has been established and expanded under the CERASORB® umbrella brand. OSBONE®, ALLOSORB® allograft and our full line of membranes round off the dental product portfolio. The versatile product variants available provide surgeons and implantologists with maximum flexibility.

CellBios is the only Indian company to develop products in medical & Biotechnology sector. We are the first in India and second in Asia to manufacture Freezing bags and Transfer bag sets for cord blood industry and first to manufacture products for Biotechnology / Bio-Process industries. CellBios is always going through a transformation to advance in this competitive world with important investments in product development for the improvement of human health. CellBios, offering new insights and manufacturing solutions to customers to achieve a breakthrough in healthcare. CellBios business is divided into five business units such as Bio-Banking (Freezing Bags, Transfer Freezing Bag, Transfer Bags, Accessories), Bio-Process (UpStream Bioprocessing, DownStream Bioprocessing, Manifold Transfer Sets, Sampling Bags, Storage Bags), Cell Therapy ( Bone Marrow Transplantation, Cord Blood Transplantation, Cord Blood Storage, Cryo Storage / Cryo Preservation, Stem Cell & Regenerative Medicine) & Medical (Urology, Nephro Care, Critical Care, Cardio Care, Infusion & Drug Delivery, Respiro Care, In-vitro Fertilisation) to serve these market segments in a more scientific and focused approach. CellBios R&D team focused on creating innovative solutions for providing better life. We provide service to our customers to expedite results with enhanced efficiency, technology transfers & meeting regulatory requirements. CellBios offers various products to meet customer expectations.